Browsing 2015 RD&E publications by Author "Zargar, H."

Now showing items 1-1 of 1

    • Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer 

      Zargar, H.; Espiritu, P. N.; Fairey, A. S.; Mertens, L. S.; Dinney, C. P.; Mir, M. C.; Krabbe, L. M.; Cookson, M. S.; Jacobsen, N. E.; Gandhi, N. M.; Griffin, J.; Montgomery, J. S.; Vasdev, N.; Yu, E. Y.; Youssef, D.; Xylinas, E.; Campain, Nick J.; Kassouf, W.; Dall'Era, M. A.; Seah, J. A.; Ercole, C. E.; Horenblas, S.; Sridhar, S. S.; McGrath, John S; Aning, J.; Shariat, S. F.; Wright, J. L.; Thorpe, A. C.; Morgan, T. M.; Holzbeierlein, J. M.; Bivalacqua, T. J.; North, S.; Barocas, D. A.; Lotan, Y.; Garcia, J. A.; Stephenson, A. J.; Shah, J. B.; van Rhijn, B. W.; Daneshmand, S.; Spiess, P. E.; Black, P. C. (Elsevier, 2015-02-01)
      BACKGROUND: The efficacy of neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (BCa) was established primarily with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), with complete response rates ...